Erbitux Review Required Six Months Because BLA Was Not Rolling, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency notes speedier reviews are generally a function of an application’s rolling status because the user fee clock does not start until the filing of the application is complete.
You may also be interested in...
Bristol/ImClone's Erbitux Clears FDA; Undergoing Two Confirmatory Trials
Erbitux is indicated for treatment of EGFR-expressing, metastatic colorectal carcinoma in combination with irinotecan or as monotherapy. Launch is expected within two weeks using product manufactured at Lonza Biologics facility.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.